Using the health assessment questionnaire to estimate preference-based single indices in patients with rheumatoid arthritis.

OBJECTIVE To estimate the relationship between preference-based measures, EuroQol (EQ-5D) and SF-6D, and the Health Assessment Questionnaire (HAQ) disability index (DI) in patients with rheumatoid arthritis (RA), and to characterize components that are predictors of health utility. METHODS Patients with RA participating in 2 studies in the UK (n = 151) and Canada (n = 319) completed the HAQ, EQ-5D, and Short Form 36 (SF-36). The SF-36, a generic measure of quality of life, was converted into the preference-based SF-6D. From these results we developed models of the relationship between the HAQ and SF-6D and EQ-5D using various regression analyses. RESULTS The optimal model developed for the EQ-5D entered levels for each item as independent variables (model 5). A root mean square error (RMSE) of 0.18 suggested relatively good predictive ability. For the SF-6D, RMSEs were lower (0.09), suggesting better predictions than for the EQ-5D, but models with more explanatory variables did not improve results (model 2 or 4 optimal). The models were able to predict actual SF-6D and EQ-5D across the range of the HAQ DI. CONCLUSION Our approach enabled calculations of quality-adjusted life years from existing trials where only the HAQ was measured. All aspects of the HAQ may not be reflected in the preference-based measures, and this method is suboptimal to direct measurement of health state utility in clinical trials. Given this limitation, our approach provides an alternative for researchers who need health-state utility values, but had not included a preference-based measure in their clinical study because of resource constraints or a desire to limit patient burden.

[1]  L. Klareskog,et al.  Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial , 2004, The Lancet.

[2]  J. Fries,et al.  The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. , 1982, The Journal of rheumatology.

[3]  P. Lipsky,et al.  Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial , 1999, The Lancet.

[4]  B. Zheng Summarizing the goodness of fit of generalized linear models for longitudinal data. , 2000, Statistics in medicine.

[5]  M. Drummond,et al.  Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case. , 2003, The Journal of rheumatology.

[6]  D. Symmons,et al.  Comment on: Modelling the cost effectiveness of TNF antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry , 2008 .

[7]  M. Gold Cost-effectiveness in health and medicine , 2016 .

[8]  Improvement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody) plus methotrexate. , 2004, Rheumatology.

[9]  D. Fryback,et al.  Report of Nationally Representative Values for the Noninstitutionalized US Adult Population for 7 Health-Related Quality-of-Life Scores , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.

[10]  Ross D Crosby,et al.  Estimating a preference-based single index for the Impact of Weight on Quality of Life-Lite (IWQOL-Lite) instrument from the SF-6D. , 2004, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[11]  J. Ware SF-36 health survey: Manual and interpretation guide , 2003 .

[12]  A. Brennan,et al.  Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. , 2004, Rheumatology.

[13]  P Wainwright,et al.  Virtual outreach: a randomised controlled trial and economic evaluation of joint teleconferenced medical consultations. , 2004, Health technology assessment.

[14]  P. Tugwell,et al.  Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. , 1993, The Journal of rheumatology.

[15]  D. Scott,et al.  Quality of life measures: use and abuse. , 2000, Bailliere's best practice & research. Clinical rheumatology.

[16]  R. Brooks EuroQol: the current state of play. , 1996, Health policy.

[17]  J. Brazier,et al.  The estimation of a preference-based measure of health from the SF-36. , 2002, Journal of health economics.

[18]  M. Drummond,et al.  Health Care Technology: Effectiveness, Efficiency and Public Policy@@@Methods for the Economic Evaluation of Health Care Programmes , 1988 .

[19]  J. Kopec,et al.  A Comparison of Four Indirect Methods of Assessing Utility Values in Rheumatoid Arthritis , 2004, Medical care.

[20]  P Barton,et al.  The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. , 2004, Health technology assessment.

[21]  Andrew Booth,et al.  A Review of the Use of Health Status Measures in Economic Evaluation , 1999, Journal of health services research & policy.

[22]  P. Dolan,et al.  Modeling valuations for EuroQol health states. , 1997, Medical care.

[23]  J. Brazier,et al.  A comparison of the EQ-5D and SF-6D across seven patient groups. , 2004, Health economics.

[24]  J. Brazier,et al.  Deriving preference-based single indices from non-preference based condition-specific instruments: converting AQLQ into EQ5D indices , 2002 .

[25]  J. Wong Cost-effectiveness of anti-tumor necrosis factor agents. , 2004, Clinical and experimental rheumatology.

[26]  A. Silman,et al.  Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. , 2006, Arthritis and rheumatism.